RxDoctor Payments Data

Andrew Kelly, MD

Family Medicine · Tulsa, OKNPI 1437492949

Payments from drug & device makers

$3,622in general payments, 2019–2025

Across 206 payments — averaging $17.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$544
  • Pfizer$520
  • GSK$400
  • AstraZeneca$381
  • Johnson & Johnson$267
  • Novo Nordisk$214
  • plus $1K from 18 others

What the payments were for

  • Food & beverage$3,57299%
  • Education$501%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,622 in reported general payments places this provider in the 80th percentile of 1,730 family medicine providers in Oklahoma.

See all family medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$92,140
Medicare patients
301
Services billed
1,797

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban149$148,442
MounjaroTirzepatide119$130,997
OzempicSemaglutide126$126,057
JardianceEmpagliflozin88$110,220
Trelegy ElliptaFluticasone/Umeclidin/Vilanter95$86,125
XareltoRivaroxaban39$43,221
FarxigaDapagliflozin Propanediol32$32,618
TrulicityDulaglutide23$24,078
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr17$17,736
Soliqua 100-33Insulin Glargine/Lixisenatide16$15,177
Atorvastatin Calcium621$14,432
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$10,000
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog12$9,386
Rosuvastatin Calcium219$8,778
SymbicortBudesonide/Formoterol Fumarate16$5,538

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$190$155,074142 claims
PfizerEliquis$520$148,442149 claims
Novo NordiskOzempic$214$126,057126 claims
Boehringer IngelheimJardiance$105$110,22088 claims
GSKTrelegy Ellipta, Anoro Ellipta$400$103,861112 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$381$48,15661 claims
Johnson & JohnsonXarelto$267$43,22139 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,730 family medicine providers in Oklahoma.

Other family medicine in Tulsa

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →